BOSTON (

TheStreet

) -- Welcome to the first ever Biotech Stock Mailbag Live Chat. The floor is yours.

I'm here for the next hour or so to answer your biotech investing questions and hopefully spark some interactive debate on the hot biotech topics of the day. This chat only works if you participate, so please keep the questions and comments flowing in the box below.

The American Society of Clinical Oncology (ASCO) meeting kicks off in a few weeks, so we can talk about hot cancer stocks like

Exelixis

(EXEL) - Get Exelixis, Inc. Report

,

YM Biosciences

( YMI) or

Dendreon

(DNDN)

.

If you're a fan of large-cap biotech stocks, we can talk about how the emergence of oral multiple sclerosis drugs is affecting

Biogen Idec

(BIIB) - Get Biogen Inc. Report

.

Celgene

(CELG) - Get Celgene Corporation Report

is dealing with controversy over secondary cancer risks tied to its most important drug Revlimid, so let's hash out the issue. How about discussing

Amgen

(AMGN) - Get Amgen Inc. Report

and the pros and cons of offering its first shareholder dividend?

I never shy away from controversial topics, so let's argue about the prospects for

Spectrum Pharmaceuticals

(SPPI) - Get Spectrum Pharmaceuticals, Inc. Report

,

Cell Therapeutics

(CTIC) - Get CTI BioPharma Corp. Report

,

Delcath Systems

TheStreet Recommends

(DCTH)

,

Cytori Therapeutics

(CYTX)

or

Radient Pharmaceuticals

( RPC).

New drug launches are a big investment theme in 2011, so bring your questions and comments regarding

Human Genome Sciences

( HGSI),

Somaxon Pharmaceuticals

( SOMX),

Avanir Pharmaceuticals

(AVNR)

or

InterMune

(ITMN)

.

It's your Biotech Stock Mailbag Live Chat, so let's get started.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here:

Adam Feuerstein

.

>To follow the writer on Twitter, go to

http://twitter.com/adamfeuerstein

.

>To submit a news tip, send an email to:

tips@thestreet.com

.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.